- Oct. 2, 2009) - Stem Cell Therapeutics Corp. ("SCT") (TSX VENTURE:SSS) announced
that Dr. Alan Moore, President and CEO, will be presenting today at the Banff
Venture Forum 2009, taking place in Banff, Alberta, October 1-2. Dr. Moore will
be providing an overview of the Company's clinical and pre-clinical stage
programs, including progress in the Phase IIb stroke trial with Drs. Steven C.
Cramer of the University of California, Irvine and Michael D. Hill of the
Foothills Hospital at the University of Calgary, as co-lead investigators; as
well as its soon-to-commence multiple sclerosis ("MS") phase II trial with
prolactin, lead by Drs. Luanne Metz and Fiona Costello of the MS Clinic at the
Foothills Medical Centre in Calgary, Alberta.
About the Banff Venture Forum
Banff Venture Forum 2009 is the premier company financing event in Canada. It
will showcase early and growth stage companies in three streams: Information
Technology, Energy Technology and Life Sciences Technology. Featured companies
will be presenting before investors from across North America with the
intention of securing the investment required to grow their businesses.
About Stem Cell Therapeutics
Corp.: Stem Cell Therapeutics Corp. is a public biotechnology company (TSX
VENTURE:SSS) focused on the development and commercialization of drug-based
therapies to treat central nervous system diseases. SCT is a leader in the
development of therapies that utilize drugs to stimulate a patient's own
resident stem cells. The Company's programs aim to repair brain and nerve
function lost due to disease or injury. The Company's extensive patent
portfolio of owned and licensed intellectual property supports the potential
expansion into future clinical programs in numerous neurological diseases such
as traumatic brain injury, multiple sclerosis, Huntington's disease,
Alzheimer's disease, and ALS.
For further information on Stem Cell
Therapeutics Corp., visit www.stemcellthera.com.
securities have not been registered under the United States Securities Act of
1933, as amended, or the securities laws of any state, and may not be offered
or sold within the United States or to, or for the account or benefit of U.S.
persons unless an applicable exemption from U.S. registration requirements is
for historical information, this press release may contain forward-looking
statements, which reflect the Company's current expectation regarding future
events. These forward-looking statements involve risk and uncertainties, which
may cause but are not limited to, changing market conditions, the successful
and timely completion of clinical studies, the establishment of corporate
alliances, the impact of competitive products and pricing, new product
development, uncertainties related to the regulatory approval process and other
risks detailed from time to time in the Company's ongoing quarterly and annual
The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.